Science

Observational study identifies drug that improves survival in sickest COVID-19 patients

Observational study identifies drug that improves survival in sickest COVID-19 patients

A drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). The findings were published in The Lancet Rheumatology on Aug. 14, and Hackensack Meridian Health researchers have updated the U.S. Food and Drug Administration and other national leaders of the findings to potentially accelerate improved outcomes.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,